Biomarkers of Parkinson's Disease: Difference between revisions
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
== Biomarkers and Parkinson's disease == | == Biomarkers and Parkinson's disease == | ||
== | === Oral biomarkers of exercise-induced neuroplasticity in Parkinson's disease === | ||
== Resources == | == Resources == | ||
Revision as of 07:47, 8 April 2022
Original Editor - Arnold Fredrick D'Souza
Top Contributors - Arnold Fredrick D'Souza, Libby McConnell, Kim Jackson and Lucinda hampton
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (8/04/2022)
An introduction to Biomarkers[edit | edit source]
The Biomarkers Definitions Working Group defines biomarkers (biological markers) as ‘‘a measurable indicator of some biological state or condition that is objectively measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.’’ Biomarkers can be used as a diagnostic tool, disease staging tool, prognostic tool, or for predicting and monitoring the clinical response to an intervention.[1] Their characteristics can be molecular, histological, radiographical, or physiological.[2]
Biomarkers and Parkinson's disease[edit | edit source]
Oral biomarkers of exercise-induced neuroplasticity in Parkinson's disease[edit | edit source]
Resources[edit | edit source]
- bulleted list
- x
or
- numbered list
- x
References[edit | edit source]
- ↑ Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.
- ↑ FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Glossary. 2016 Jan 28 [Updated 2021 Nov 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK338448/
